CTX-471 for NCAM-positive advanced neuroendocrine tumors
Part of Cancer clinical trials.
This study tests an experimental drug called CTX-471 in people with a certain type of advanced neuroendocrine cancer that has a protein called NCAM on the cells. It is for patients who have already tried chemotherapy and need other options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your neuroendocrine tumor or carcinoma is Grade 3 (more aggressive) and has spread or cannot be removed with surgery.
- You have already tried at least one chemotherapy treatment, and there are no other standard treatments left that work for you.
- A lab test on a recent or stored tumor sample shows it has a protein called NCAM on the cells.
- You are in fairly good health, able to care for yourself and walk around.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ADCT-701 for people with certain rare cancers (neuroendocrine tumors, adrenal cancer, or a type of nerve tumor) that have come back or spread. The drug is an antibody-drug conjugate, which works like a targeted missile to kill cancer cells while trying to spare healthy ones.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This study tests cabozantinib, a targeted therapy that blocks tumor growth, in people with advanced neuroendocrine tumors who have already tried other treatments. It may offer a new option if your doctor plans to use this drug.
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
This trial tests a new drug called CTX-8371 for people with advanced cancers (melanoma, head and neck, lung, triple-negative breast, or Hodgkin lymphoma) that have stopped responding to standard treatments, especially immunotherapy. It is a first-in-human study, meaning doctors are learning if the drug is safe and how well it works.
This trial tests NPX372, a new type of immunotherapy designed to fight several types of advanced cancer that haven't responded to standard treatments. It works by combining two immune signals to help your body's immune system recognize and attack cancer cells.
Hear when a new Neuroendocrine Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.